https://www.ironwoodtherapeuticwellness.com/about daily 0.75 2026-04-17 https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1747094373231-RKYV9ADEE6IZC3H1T126/unsplash-image-BjqFEPt06Hg.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1747094567958-8HC3N2CV2KE77AW5B027/unsplash-image-od3jdQqX8O8.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1747094660105-62QWLA0CIQL1TRWR40JQ/unsplash-image-k5DHvljGm4E.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1747094973531-YRWAI168EHNLXBPQXN3B/unsplash-image-aL9BguRRo8M.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1747095108799-857N28WL8S9F6L3DV7B7/unsplash-image-9nVF3PK0cqY.jpg https://www.ironwoodtherapeuticwellness.com/home daily 1.0 2026-05-18 https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/7f0b3382-b929-4a78-90b2-8a619d84d76b/Ironwood+Logo.png https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/7038922a-f66a-43fc-a575-20dcd46c2ac3/kaileegraduation-31.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/5875a04d-c672-450a-beb5-67507b87d68a/Brendan.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/578ea5d7-7d78-4c52-ac24-2b9ecc845181/Gracie.jpeg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/bd368361-8b4d-40ba-bd91-71e7fd041085/Sarah.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/894403c5-9d6f-4611-b31a-6d9d74139066/320x400.jpeg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/6ab93882-1555-4a64-9cee-4e817e84a15c/Chloe.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1756db9a-6dba-4a0c-86d0-2030856eccb3/Ironwood+Tree.jpg https://www.ironwoodtherapeuticwellness.com/faqs daily 0.75 2026-03-18 https://www.ironwoodtherapeuticwellness.com/provider-referrals daily 0.75 2026-04-06 https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1755875167235-5T7V1426TF4T12DXA6FU/unsplash-image-DFtjXYd5Pto.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1755875946512-FVZER2Y3WCZW38OOE10D/unsplash-image-iSiBtC93Dok.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1755875039608-N68PXUW1S9HGX8GQK354/unsplash-image-JsDpqhyGtV0.jpg https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/1755875824168-UBD0QWX4HATOQUA62TXR/unsplash-image-YAfeGU2YrUQ.jpg https://www.ironwoodtherapeuticwellness.com/good-faith-estimate daily 0.75 2026-03-18 https://www.ironwoodtherapeuticwellness.com/consumer-information-notice daily 0.75 2026-02-05 https://www.ironwoodtherapeuticwellness.com/spravato daily 0.75 2026-05-18 https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/eb8302e3-7780-4b0c-acd9-5ec58411f0cc/spravatologo.jpg Spravato - How SPRAVATO® Works SPRAVATO® is different because it targets glutamate, the most abundant excitatory neurotransmitter in the brain The primary antidepressant activity of SPRAVATO® is not believed to directly involve inhibition of serotonin or norepinephrine reuptake. The precise mechanism of action (MOA) is unknown. SPRAVATO® is an NMDA receptor antagonist. An NMDA receptor is an ionotropic glutamate receptor. NMDA=N-methyl-D-aspartate. Clinical study results suggest that glutamate transmission is abnormally regulated in multiple areas of the brain of individuals with depression Antagonism of the NMDA receptor and AMPA receptor activation leads to downstream release of BDNF and activation of kinases BDNF expression and downstream signaling are thought to enhance neurogenesis and mediation of synaptic excitability and plasticity It is important to note that the relationship between this pathway and the clinical effects of depression have not been established AMPA=α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. BDNF=brain-derived neurotrophic factor. https://images.squarespace-cdn.com/content/v1/67f17c5828a1eb0070f616d2/5645c24f-9f56-43a3-8499-776602f0a2fd/spravato_nasal_spray.jpg Spravato - Indications SPRAVATO® is for use alone or in combination with an oral antidepressant for: Adults with treatment-resistant depression (MDD patients who have had an inadequate response to 2 or more oral ADs) SPRAVATO® is for use in combination with an oral antidepressant for: Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (MDSI) Limitations of Use: The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. SPRAVATO® is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO® as an anesthetic agent have not been established. AD=antidepressant. MDD=major depressive disorder.